Posts by Sam
PharmaLegacy Research LLC, dba. BTS Research Announces Expansion of their Headquarters & In Vitro Labs in their New San Diego Facility
PharmaLegacy Research LLC, dba. BTS Research Announces Expansion of their Headquarters & In Vitro Labs in their New San Diego Facility San Diego, CA February 1, 2025 San Diego, California — BTS Research, a leading provider of in vitro and in vivo preclinical drug development services, announces the expansion of its San Diego operations. The…
Read MoreBTS Research Earns Full AAALAC Accreditation Renewal
BTS Research Earns Full AAALAC Accreditation Renewal Continued Commitment to Excellence in Laboratory Animal Care San Diego, California — BTS Research a PharmaLegacy company is pleased to announce that the company has successfully renewed its FULL ACCREDITATION from the AAALAC International Council on Accreditation, recognizing its unwavering dedication to the highest standards in laboratory animal…
Read MoreExpert Panel Recommends Authorization of Pfizer’s COVID-19 Vaccine for Kids Aged 5-11
Pfizer/BioNtech’s Emergency Use Authorization (EUA) application for a COVID-19 vaccine for young children has cleared its first regulatory hurdle. Source: Drug Industry Daily
Read MoreFDA Denies Petition to Pull EUAs for Moderna, J&J COVID-19 Vaccines
The FDA has rejected a citizen petition seeking to revoke the Emergency Use Authorizations (EUAs) of both the Moderna and Johnson & Johnson (J&J) COVID-19 vaccines. Source: Drug Industry Daily
Read MoreFDA Lags Far Behind EMA, Health Canada in Proactively Releasing Drug Data
The FDA is outperformed by the European Medicines Agency (EMA) and Health Canada when it comes to proactively releasing data on drug approvals, says a new study ― prompting concerns about the FDA’s relative transparency. Source: Drug Industry Daily
Read MoreModerna’s Interim Data on Kids Age 6 to 12 Shows Strong Vaccine Effectiveness
Moderna released top line data yesterday from a pediatric study of its mRNA COVID-19 vaccine, which showed a half-dose of the vaccine to be safe and effective in kids ages six up to 12 years old. Source: Drug Industry Daily
Read MoreEli Lilly Seeks FDA Approval for Experimental Alzheimer’s Drug
During its third-quarter earnings report, Eli Lilly announced that it’s pursuing accelerated approval for the investigational Alzheimer’s drug donanemab ― and that it also plans to evaluate the therapy compared to Biogen’s Aduhelm (aducanumab) in a head-to-head study. Source: Drug Industry Daily
Read MoreAstraZeneca Continues Its Hit Parade With Yet Another Imfinzi Win
AstraZeneca has scored another win with Imfinzi (durvalumab), showing that the checkpoint inhibitor in combination with standard chemotherapy improved both overall and progression-free survival for patients with advanced biliary tract cancer (BTC), a rare, aggressive disease with extremely low 5-year survival rates. Source: Drug Industry Daily
Read MoreDrug Price Negotiating Muscle for Medicare Likely to Be Modest in Final Spending Bill
As Congress races to finalize details on President Biden’s signature social spending package by week’s end, a provision allowing Medicare to negotiate prescription drug prices is expected to stay in the bill, but likely in a diluted form. Source: Drug Industry Daily
Read MoreNovartis’ Canakinumab Just Can’t Get the Magic Back
For the second time, Novartis’ workhorse anti-inflammatory, Ilaris (canakinumab), has failed to prove its mettle as an anti-cancer agent. Source: Drug Industry Daily
Read More